Member Info for PM2022

It takes time, MONEY and the correct execution. At the current market cap only see this going down just my opinion. But good to read another company and what they are doing and the difficulties faced.

CiRT orders in the second half of the financial year were 25% increased on the first half. The final financial quarter ended with 95 tests for September, bringing the total number of tests ordered since launch to 1,266. A total of 671 tests were ordered in the financial year.

Following the launch of the PROWES Registry Study - a prospective observational study - at up to 12 sites across the US, with up to 2,500 patients to expedite the inclusion of CiRT into the National Comprehensive Cancer Network (NCCN) Guidelines - three regional study sites have been onboarded to date. CiRT tests carried out in the study are being run on normal commercial terms through our CLIA-accredited labs.

By the end of August, it was evident that the majority of CiRT orders were now coming through the PROWES initiative and that the CiRT test would need to be included in NCCN Guidelines before we could expect significant traction from oncologists. Consequently, the Company has been able to reallocate its field sales resources to growing orders for the PSE test, without increasing the cost base.

In the next financial year, the main focus of the Group's CiRT team will be on completion of patient enrolment into PROWES, alongside continuing to support those oncologists already using the test in their day-to-day practice.

The Group will also shortly begin running CiRT tests on blood samples from patients enrolled in a clinical trial of an immune checkpoint inhibitor in endometrial cancer, for a top 10 pharma company.

Historically we all know how that goes on the AIM market. it needs to produce fairly big to justify the current valuation and before the next placing in my opinion. Name me one AIM company that has gone from revenue that we have here to 20 million invoiced revenue paid in only a few weeks. It does not happen. It does take time and cost and is a slow process but personally I think they will be lucky to get 1 million invoiced profit in the next 18 months therefore how are you valuing this at 14 million as a loss making company at present.

I don't think anyone can argue with that. Very fair comment.

No, you should be banned for ramping here. Your talking 4p 25/30 million range when the company is burning far more cash than it makes is nonsense.

To justify a 30 million market cap the company in my opinion should be making 20 million a year profit. GDR is loss making and sorry all this is pie in the sky figures.

Difficult to justify current valuation and even more difficult to see where profit will be made to cover higher monthly costs.

This is not an echo chamber of rampers it is to debate the advantages and disadvantages but I see more negatives and nothing concrete.

You don't get a contract worth many millions in one instant and even if you did I feel it is priced in. How are these tests being produced and manufactured? what is the profit per test? Surely more staff are needed adding to huge monthly cash burn.

It is more likely they might get a contract of about 40/50k at some point enough to cover roughly a few days work. It takes time and money.

Therefore I feel at 13 million the valuation is very high. Financials are very poor with high cash burn. Then you need to worry about where additional funding comes from in a difficult market?

You are shouting pie in the sky figures. Crazy. Show me an RNS that shows me the value of a huge contract? All pie in the sky figures. As you know it takes time in my view the timing is wrong and the entry price is very high but that is down to others to decide.

FINANCIAL HIGHLIGHTS

· Revenue and other income of £0.24m (H1 2022/3: £0.02m)

· R&D spend of £1.9m (H1 2022/3: £2.0m)

· Operating loss of £2.4m (H1 2022/3: £2.7m)

It is an opinion not a given but do the maths and work it out yourself. If you suddenly think they will start generating like 500k per month from hardly anything per month ignoring all the time and work it takes including manufacturing etc then you are doing the same.

It is highly likely a raise will be needed early 2025 and based on cash burn it will likely be a large one. Fair opinion.

The simple reality is how it is and I am looking for something to justify the market cap and high cash burn which I cannot find. You are free to debate me as this is what this board is for. Not looking for oh but they will get a billion pound contract tomorrow morning. Yeah right.

One thing I learnt from AIM stocks never fall in love. Look at the real revenue vs costs vs market cap and DYOR. Don't listen to rampers.

Not ramping or deramping but just saying here it does not add up. Market cap of about 13 million is too high and the cash burn is very high and a long way from generating anything to justify it.

Would you buy a ferrari worth 100k for 10 million pounds. This is how it feels to me here.

So what FDA approves will still have a long way to go to manufacture and sell these products. Initial contracts might be worth around the 50k region generating peanuts as revenue which I think will tank the share price to 0.1p range. It needs lots of cash to bring in large revenue for large scale production, distribution and staff expansion costs. AFTER THE NEXT PLACING might be a better time in my opinion.

Two outcomes needed to justify an increase in SP here:

1) No placing. Looking at the current revenue and cash burn that seems highly improbable.

2) Needs contracts in excess of about over 5/10 million in revenue in the next few weeks to justify the current market cap and therefore avoid a low placing.

Just my opinion but look at the figures. Does it really justify a market cap of 12 million pounds already generating only low 6 figure revenues at present and burning around 600k per month.

Look at the market cap 12 million.

Look at the financials massive cash burn per month with hardly any revenue. Comedian. This should be 0.1p in my honest opinion until proven by a valued contract or financials.

I have seen numerous AIM companies with various tests. They don't do much when it comes to revenue. Takes time and high costs to manufacture, produce, expand and eventually sell at a good profit. Profit margins are low.

At 12 million market cap in my opinion it is over inflated. Then you have to worry about funding early 2025 and would likely drift into those months. In my view I would like to wait and see but just my opinion.

Emerard, you will only have yourself to blame when this tanks. Where is the justification for the valuation of 14 million?

So what FDA approves will still have a long way to go to manufacture and sell these products. Initial contracts might be worth around the 50k region generating peanuts as revenue which I think will tank the share price to 0.1p range. It needs lots of cash to bring in large revenue for large scale production, distribution and staff expansion costs. AFTER THE NEXT PLACING might be a better time in my opinion.

Two outcomes needed to justify an increase in SP here:

1) No placing. Looking at the current revenue and cash burn that seems highly improbable.

2) Needs contracts in excess of about over 5/10 million in revenue in the next few weeks to justify the current market cap and therefore avoid a low placing.

Just my opinion but look at the figures. Does it really justify a market cap of 12 million pounds already generating only low 6 figure revenues at present and burning around 600k per month.

10 bag 140 million. Stop ramping wild figures.

Hi Laura,

Yes the same person who was shouting crazy numbers for 4D which then went bust.

The same person who was shouting £50 range for NYCT and now around 50p.

The same person that was shouting 150p for Valirx now 1p and many other companies.

DYOR as always, do not listen to rampers. Bottom line look at the financials here. Poor financials market cap over inflated it will take a likely 10 million contract to justify current market valuation.

My honest take is GDR should be valued at 1/2 million at the moment therefore 0.2/0.3p fair price until cash burn is under control and they can demonstrate profitability through very valuable contracts. That is still to be done anything less than a huge deal I see this crashing in my opinion.

If that fails the large cash burn will likely dilute holders here with a requirement for a very large placing to cover costs. I will wait until the next placing and see where we are.

Poor financials. No you will not get a big lump of cash worth millions before the next placing in my opinion. Be careful here:

Go based on current financials or actual RNS detailing contract values not on ramps. Nothing more than rampers here:

FINANCIAL HIGHLIGHTS

· Revenue and other income of £0.24m (H1 2022/3: £0.02m)

· R&D spend of £1.9m (H1 2022/3: £2.0m)

· Operating loss of £2.4m (H1 2022/3: £2.7m)

I just don't see justification for such a high market cap.

1) Long way to produce, manufacture and sell the products. I just don't see anything more than a six figure contract months down the line so expect a significant drop.

2) Might have long term potential but current costs are way too high. Better to wait for the placing in my opinion which could result in a very significant discount and dilution. Maybe then it might be good.

3) Currently valued 14 million with zilch in current revenue. Not enough to justify this and this could drop down very fast at this over inflated price.

Happy to wait and see. From past experience never buy a stock on a spike. At 14 million with little revenue I would be careful here.

All just rampers here but no real significant invoiced deals. My guess is they will likely need 10 million pounds in the next placing to cover increasing costs for 18 months.

Also I think the market will tank with Israel and Iran war on the horizon going into November so cheaper prices might be on offer.

Likely a small premium placing with warrants given the current market cap. Just my guess but looking at another stock involving the same broker might just follow the same strategy if they can get buyers in. I can see that happening if either 201 or 401 are likely by year end so not as what everyone hopes.

Pursuant to the Fundraising, in aggregate, 714,285,714 Fundraising Shares will be issued at the Fundraising Price which represents a premium of 59 per cent.

Only time will tell.

I would disagree. Val has had numerous big moves roughly from 1p to 10p, 3p to 74p and 6p to 66p range so some would have made big money during those times although recently the trend has been downwards. They need a big move again from here.

The company under George and Satu was different to what Suzy and the current board had taken over in terms of strategy. The strategy is different and these guys are doing different to what George and Satu were doing at the time. You cannot get that mixed up. Progress is being made but is slow.

201 and 401 you can do what you want but both have LOI so therefore I don't think you are in a position to write it off. Obviously results were promising but larger trials are needed.

It would not surprise me if you were a huge believer in 201 and 401. I suspect you want sellers so you can buy more.

Yeah but why are you here? Because you want to buy cheaper or are we supposed to believe because you are here to save the world. Yeah right.

From past experience with other companies selling testing products from Covid days, manufacturing and production costs are significant. If they were burning about 400k and they have a product that will likely increase overtime before you see the rewards.

It is all relative at this moment of time so 10 million is far too high. If they are not even covering monthly costs or making a profit then how could one justify the current valuation. If it is based on potential then I doubt you see a contract worth many millions flying through. I suspect IN THE FUTURE the maximum profit they hit is a 6 figure sum after costs but again 10 million is far too high.